These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33463108)

  • 1. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.
    Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O
    Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients.
    Karimi L; Eskandari N; Shaygannejad V
    Neuroimmunomodulation; 2022; 29(3):177-185. PubMed ID: 34808619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
    Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
    Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
    Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
    Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
    Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
    Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
    Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
    Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in circulating T cell functional subpopulations in interferon-beta treated multiple sclerosis patients: A pilot study.
    Monteiro A; Rosado P; Rosado L; Fonseca AM; Paiva A
    J Neuroimmunol; 2020 Feb; 339():577113. PubMed ID: 31778850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis.
    Naghavian R; Ghaedi K; Kiani-Esfahani A; Ganjalikhani-Hakemi M; Etemadifar M; Nasr-Esfahani MH
    PLoS One; 2015; 10(5):e0124555. PubMed ID: 25938517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th17 and Th1 Lymphocytes Are Correlated with Chronic Periodontitis.
    Chen XT; Chen LL; Tan JY; Shi DH; Ke T; Lei LH
    Immunol Invest; 2016; 45(3):243-54. PubMed ID: 27019379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus-like effects of type I interferon in autoimmune diseases.
    Axtell RC; Raman C
    Immunol Rev; 2012 Jul; 248(1):23-35. PubMed ID: 22725952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes.
    Arellano G; Acuña E; Reyes LI; Ottum PA; De Sarno P; Villarroel L; Ciampi E; Uribe-San Martín R; Cárcamo C; Naves R
    Front Immunol; 2017; 8():753. PubMed ID: 28713377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sema4A is implicated in the acceleration of Th17 cell-mediated neuroinflammation in the effector phase.
    Koda T; Namba A; Kinoshita M; Nakatsuji Y; Sugimoto T; Sakakibara K; Tada S; Shimizu M; Yamashita K; Takata K; Ishikura T; Murata S; Beppu S; Kumanogoh A; Mochizuki H; Okuno T
    J Neuroinflammation; 2020 Mar; 17(1):82. PubMed ID: 32169103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.
    Milosevic E; Dujmovic I; Markovic M; Mesaros S; Rakocevic G; Drulovic J; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2015 Oct; 287():64-70. PubMed ID: 26439963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.
    Gross CC; Schulte-Mecklenbeck A; Hanning U; Posevitz-Fejfár A; Korsukewitz C; Schwab N; Meuth SG; Wiendl H; Klotz L
    Mult Scler; 2017 Jun; 23(7):1025-1030. PubMed ID: 27481205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.
    Fattahi M; Eskandari N; Sotoodehnejadnematalahi F; Shaygannejad V; Kazemi M
    Cell J; 2020 Apr; 22(1):92-95. PubMed ID: 31606972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells.
    Sweeney CM; Lonergan R; Basdeo SA; Kinsella K; Dungan LS; Higgins SC; Kelly PJ; Costelloe L; Tubridy N; Mills KH; Fletcher JM
    Brain Behav Immun; 2011 Aug; 25(6):1170-81. PubMed ID: 21420486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].
    Zhang X; Zhang Q; Shi X; Yin R; Zhang Z; Hou X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jul; 29(7):751-3. PubMed ID: 23837989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.